Zidesamtinib Patent Expiration
Zidesamtinib was first introduced by Nuvalent Inc
Zidesamtinib Patents
Given below is the list of patents protecting Zidesamtinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jideytro | US12043626 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds | Sep 30, 2042 | Nuvalent |
| Jideytro | US12630560 | Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether Compounds | Sep 30, 2042 | Nuvalent |
| Jideytro | US11542278 | May 05, 2041 | Nuvalent | |
| Jideytro | US12054498 | Heteroaromatic Macrocyclic Ether Chemotherapeutic Agents | May 05, 2041 | Nuvalent |
Zidesamtinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Zidesamtinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Nuvalent Inc. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |